David McWilliams
CIK 1303311 · CEO · last filed 2024-12-27
David McWilliams is a CEO who has filed 11 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for GLSI, was dated Dec 27, 2024. Across all open-market trades the lifetime net is +$28.6K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $11.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$11.41M
3
11
$28.6K
Filer Profile
HOUSTON, TX 77054-9816
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GLSI | Director | 620,301 | $18.39 | $11.41M | $28.6K | 6 | 2024-12-27 |
| Acer Therapeutics Inc. (OPXAW) Delisted | CEO | — | — | — | $0 | 4 | 2009-08-27 |
| Acer Therapeutics Inc. (OPXA) Delisted | Chief Executive Officer | — | — | — | $0 | 1 | 2007-06-19 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-27 | GLSI | Grant (A) | — | $0 | EDGAR |
| 2022-06-24 | GLSI | Grant (A) | — | $0 | EDGAR |
| 2021-12-16 | GLSI | Buy (P) | +200 | $5.5K | EDGAR |
| 2020-11-24 | GLSI | Buy (P) | +1,500 | $8.1K | EDGAR |
| 2020-09-30 | GLSI | Mixed | +171,622 | $0 | EDGAR |
| 2020-09-29 | GLSI | Buy (P) | +2,608 | $15.0K | EDGAR |
| 2009-08-27 | Acer Therapeutics Inc. (OPXAW) Delisted | Mixed | — | $0 | EDGAR |
| 2009-02-09 | Acer Therapeutics Inc. (OPXAW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-06-30 | Acer Therapeutics Inc. (OPXAW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-05-08 | Acer Therapeutics Inc. (OPXAW) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.